Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure

Anti-CD38 monoclonal antibody (MoAB) therapy has significantly improved the prognosis of patients with multiple myeloma. However, not all patients sustain durable responses. We aimed to describe the natural history of patients relapsed or refractory (R/R) to CD38 MoAB therapy. We performed a single-...

Descripción completa

Detalles Bibliográficos
Autores principales: Zamanillo, Irene, Medina de Alba, Lucia, Gil, Rodrigo, de la Puerta, Rosalia, Alonso, Rafael, Jimenez-Ubieto, Ana, Cedena, Maria Teresa, Calbacho, Maria, Ayala, Rosa, Martinez-Lopez, Joaquin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532632/
https://www.ncbi.nlm.nih.gov/pubmed/37763245
http://dx.doi.org/10.3390/life13091841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532632/
https://www.ncbi.nlm.nih.gov/pubmed/37763245
http://dx.doi.org/10.3390/life13091841

Ejemplares similares